Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2007

Alethia and Biosite Commit to Mab Development in Ovarian Cancer

  • Alethia Biotherapeutics inked a deal with Biosite for the development of recombinant Mabs against validated targets in ovarian cancer.

    "The development of monoclonal antibodies is directly in line with our drug development strategy to provide disease-specific targets for focused therapeutics,” says Mario Filion, executive vp and CSO of Alethia. “The outcome of this collaboration will constitute the first candidate leads to achieve this objective."

    Under the terms of the exclusive collaborative agreement, Alethia will provide Biosite with access to highly specific functional targets that will be evaluated as markers for ovarian cancer. In return, Biosite will provide Alethia with Mabs for validated disease-specific targets to accelerate Alethia's R&D.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »